Skip to main content
. 2014 Jul 11;16(12):1618–1629. doi: 10.1093/neuonc/nou132

Fig. 3.

Fig. 3.

Inhibition of glioma cell proliferation by EFTUD1 downregulation. (A) Effect of EFTUD1 siRNAs on cell proliferation in U87MG and U251MG glioma cells. Cell viability was analyzed 0, 2, 4, and 6 days after transfection. Results are presented as fold relative to the cell viability in mock-treated cells at day 0. Data are mean ± S.D. (bars) of 3 experiments. **P < 0.01 using 1-way ANOVA. (B) Cell-cycle analysis of EFTUD1 siRNA-transfected glioma cells with and without nocodazol (0.1 mg/mL for 12 h). Cells were fixed with 70% ethanol 4 days after transfection, treated with RNAse, and stained with propidium iodide. Cell-cycle distributions were analyzed by flow cytometry. Data are shown as the percentage of cells in various phases of the cell cycle. (C) Effect of EFTUD1 siRNAs on apoptosis in U87MG and U251MG glioma cells. Caspase 3/7 activity in glioma cells was analyzed 6 days after siRNA transfection. Caspase 3/7 activity was normalized to viable cell signals measured by the CellTiter Glo luminescent cell-viability assay. Relative caspase 3/7 activity is presented as fold relative to this normalized value found in control siRNA-transfected cells. Results are mean ± S.D. (bars) of 3 experiments. *P < .05, **P < .01 using 1-way ANOVA. (D) Western blot analysis of p53 and p21 in U87MG and U251MG 3 days after siRNA transfection. β-Actin was used as a loading control.